Advertisement

Organisation › Details
Ionis Pharmaceuticals Inc. (Nasdaq: IONS)
Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over three dozen drugs in development. SPINRAZA® (nusinersen) has been approved in the U.S., Europe, Japan and Canada for the treatment of spinal muscular atrophy (SMA). Biogen is responsible for commercializing SPINRAZA. Drugs that have successfully completed Phase 3 studies include inotersen (IONIS-TTRRx), an antisense drug Ionis is developing to treat patients with TTR amyloidosis, and volanesorsen, an antisense drug discovered by Ionis and co-developed by Ionis and Akcea Therapeutics to treat patients with either familial chylomicronemia syndrome or familial partial lipodystrophy. Akcea, an affiliate of Ionis, is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. If approved, volanesorsen will be commercialized through Ionis' affiliate, Akcea. Both inotersen and volanesorsen are progressing toward regulatory filings for marketing authorization. Ionis' patents provide strong and extensive protection for its drugs and technology. *
![]() |
Start | 2015-12-01 renamed |
Group | Ionis Pharmaceuticals (Group) | |
Predecessor | Isis Pharmaceuticals Inc. (Nasdaq: ISIS) | |
![]() |
Industry | pharmaceutical |
Industry 2 | antisense drug | |
![]() |
Person | Crooke, Stanley T. (Isis Pharmaceuticals 200604 CEO) |
![]() |
Region | Carlsbad, CA |
Country | United States (USA) | |
Street | 2855 Gazelle Court | |
City | 92010 Carlsbad, CA | |
Tel | +1-760-931-9200 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for �About Section�: Ionis Pharmaceuticals, Inc.. (8/11/17). "Press Release: Ionis to Independently Advance Inotersen and Ionis-FB-L Rx". Carlsbad, CA. | ||
Record changed: 2019-07-13 |
Advertisement
![Picture [iito] Plain Stupid Simple 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-plain-stupid-simple.jpg)
More documents for Ionis Pharmaceuticals (Group)
- [1] ProQR Therapeutics N.V.. (10/29/18). "Press Release: ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals". Leiden....
- [2] Roche. (8/3/18). "Press Release: PRIME Designation Granted by European Medicines Agency for RG6042 for Treatment of Huntington’s Disease". Basel....
- [3] Ionis Pharmaceuticals, Inc.. (7/11/18). "Press Release: Akcea and Ionis Announce Approval of Tegsedi (inotersen) in the European Union". Cambridge, MA & Carlsbad, CA....
- [4] Ionis Pharmaceuticals, Inc.. (8/11/17). "Press Release: Ionis to Independently Advance Inotersen and Ionis-FB-L Rx". Carlsbad, CA....
- [5] Bayer AG. (5/4/15). "Press Release: Antisense Approach for Clotting Disorders – Bayer Licenses ISIS-FXI Rx from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis [Not intended for U.S. and UK Media]". Leverkusen....
- [6] AstraZeneca plc. (12/11/12). "Press Release: AstraZeneca and Isis Pharmaceuticals Form Strategic Alliance on RNA Therapeutics for Cancer"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top